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Objective: Conventional chemotherapy and radiotherapy produce marginal survival benefits in pancre-
atic cancer, underscoring the need for novel therapies. The aim of this study is to develop an adoptive
T cell transfer approach to target tumours expressing prostate stem cell antigen (PSCA), a tumour-
associated antigen that is frequently expressed by pancreatic cancer cells.
Methods: Expression of PSCA on cell lines and primary tumour samples was confirmed by immuno-
histochemistry. Healthy donor- and patient-derived T cells were isolated, activated in vitro using CD3/
CD28, and transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) targeting
PSCA. The ability of these cells to kill tumour cells was analysed by chromium-51 (Cr51) release.
Results: Prostate stem cell antigen was expressed on >70% of the primary tumour samples screened.
Activated, CAR-modified T cells could be readily generated in clinically relevant numbers and were
specifically able to kill PSCA-expressing pancreatic cancer cell lines with no non-specific killing of
PSCA-negative target cells, thus indicating the potential efficacy and safety of this approach.
Conclusions: Prostate stem cell antigen is frequently expressed on pancreatic cancer cells and can be
targeted for immune-mediated destruction using CAR-modified, adoptively transferred T cells. The safety
and efficacy of this approach indicate that it deserves further study and may represent a promising novel
treatment for patients with pancreatic cancer.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer-related
mortality in the USA with a 5-year survival rate of <5% (http://
seer.cancer.gov/csr/1975_2007/index.html). Although the inci-
dence of pancreatic cancer is lower than those of breast, prostate
and colon cancer, no cancer is associated with a more dismal
prognosis. Because its symptoms in the early stages of disease are
vague, and effective screening tests are lacking, about 80% of
patients are diagnosed with locally advanced or metastatic
pancreatic cancer. Even among theminority of patients with local-
ized disease that is eligible for surgery, 5-year survival is only 20%,
which is much inferior to outcomes of complete resection in all
other cancers. It is an understatement to say that pancreatic cancer
is resistant to surgery and conventional chemoradiation. After
resection with negative margins and adjuvant chemoradiation,
most patients have recurrent disease in little over a year after
surgery and die within 2 years of surgery. Treatment of pancreatic
cancer remains an enormous clinical challenge. Therefore, novel
therapeutic strategies are urgently needed and adoptive T cell
transfer represents a promising approach.1
Since the targeting of chemoresistant tumours using T cell
therapy was demonstrated, interest has increased in combining
these strategies and recruiting the host immune system to help
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eradicate disease that remains after conventional therapy.2,3 We
and others have shown that the infusion of T cells engineered with
tumour specificity through the transgenic expression of a chi-
meric antigen receptor (CAR) can effectively treat even dissemi-
nated malignancies including neuroblastomas and B cell
tumors.4–8 Chimeric antigen receptors combine the antigen-
binding properties of a monoclonal antibody with the lytic capac-
ity of T cells, thus allowing transgenic cells to recognize both
protein and non-protein antigens on tumour cells and to kill
target cells in a major histocompatibility complex (MHC)-
independent fashion.9,10
In the current study, we sought to extend T cell therapy to the
treatment of pancreatic cancer. However, a prerequisite step
involved the identification of a target antigen which is present on
the cell surface and is expressed or overexpressed on malignant
cells, but has limited expression on vital organs. Prostate stem cell
antigen (PSCA) meets all these criteria. This antigen is a glyco-
sylphosphatidylinositol (GPI)-anchored cell surface protein
thought to be involved in intracellular signalling, although much
remains unknown about its physiological function.11 It is upregu-
lated in several major cancers, including prostate, bladder and
pancreatic cancers, but in normal cells its expression is restricted,
making it an ideal target antigen.11,12
We now show, using immunohistochemistry (IHC), that PSCA
is overexpressed in both pancreatic cancer cell lines and in the
majority of pancreatic ductal adenocarcinomas. To target this
antigen, we constructed a retroviral vector encoding a CAR-
targeting PSCA and demonstrated that both normal donor- as
well as patient-derived T lymphocytes can be genetically modified
to express this CAR. Transgenic cells are able to specifically kill
PSCA-positive tumour cell lines without impacting non-antigen
expressing targets and can be produced in large numbers,13 thus
demonstrating the feasibility of this approach in a clinical setting.
Materials and methods
Donors and cell lines
Pancreatic cancer cell lines CAPAN-1, CFPAC, PL45 and ASPC-1
were obtained from the American Type Culture Collection
(ATCC, Rockville, MD, USA). Cells were maintained in a humidi-
fied atmosphere containing 5% carbon dioxide (CO2) at 37 °C.
Peripheral blood and tumour samples were collected from pan-
creatic cancer patients and healthy volunteers with their informed
consent under Baylor College of Medicine Institutional Review
Board-approved protocols. Tumour arrays (human cancers B
IMH-327) were purchased from Imgenex Corp. (San Diego, CA,
USA).
OKT3 blasts generation
Peripheral blood mononuclear cells (PBMCs) obtained from
healthy donors and patients with pancreatic cancer were activated
with OKT3 (1 mg/ml) (Ortho Biotech, Inc., Bridgewater, NJ,
USA) and CD28 (Becton Dickinson & Co., Mountain View, CA,
USA) antibodies (1 mg/ml) and plated in a non-tissue culture-
treated 24-well plate at 1 ¥ 106 PBMCs/2 ml complete media
(RPMI 1640; Gibco BRL Life Technologies, Inc., Gaithersburg,
MD, USA) containing 45% Clicks medium (Irvine Scientific, Inc.,
Santa Ana, CA, USA), 10% foetal calf serum (FCS) (HyClone
Laboratories, Inc., Logan, UT, USA) and 2 mM L-glutamine
(Gibco BRL Life Technologies, Inc.). On day 1 after activation, the
cells were supplemented with recombinant human interleukin-2
(rhIL-2, 100 U/ml, Proleukin; Chiron Corp., Emeryville, CA,
USA) and subsequently split and fed with fresh media plus IL-2
(50 U/ml).
Generation of retroviral constructs and
retroviral transduction
We synthesized (DNA 2.0) a human codon-optimized single-
chain variable fragment (scFv) of PSCA based on a published
sequence.14,15 The scFv fragment was cloned in frame with the
human IgG1-CH2CH3 domain and with the z-chain of the TCR/
CD3 complex in the SFG retroviral backbone, previously estab-
lished in our laboratory.4,5 To produce the retroviral supernatant,
293T cells were co-transfected with the CAR-PSCA vector, the
Peg-Pam-e plasmid containing the sequence for MoMLV gag-pol,
and the DRF plasmid containing the sequence for the RD114
envelope, using the Fugene6 transfection reagent (Roche Diagnos-
tics Corp., Indianapolis, IN, USA), according to the manufactur-
er’s instructions. Supernatant containing the retrovirus was
collected at 48 h and 72 h post-transfection, filtered (using a
0.45-mm filter) and stored at -80 °C.5,16,17
T lymphocyte transduction
For transduction, 0.2 ¥ 106/ml OKT3/CD28-activated PBMCs
were plated in complete media in a non-tissue culture-treated
24-well plate (1 ml/well) pre-coated with a recombinant fibronec-
tin fragment (FN CH-296; Retronectin; Takara Shuzo Co. Ltd,
Otsu, Japan). After the addition of viral supernatant (1 ml/well),
the cells were spun at 1000 g for 30 min, and then transferred to
the 37 °C, 5% CO2 incubator. Expression of CARs on T lympho-
cytes was measured 72 h post-transduction by flow cytometry. To
detect CAR-transduced cells, T lymphocytes were stained with a
monoclonal antibody Fc-specific cyanine-Cy5-conjugated (Fc-
gCy5) provided by Jackson ImmunoResearch Laboratories, Inc.
(West Grove, PA, USA), which recognizes the IgG1-CH2CH3
component of the receptor. Cells were analysed using a FACScan
(Becton Dickinson & Co.) equipped with the filter set for four
fluorescence signals. Cells were maintained or expanded in com-
plete media supplemented with rhIL-2 (50 U/ml) every 3 days.
Cytotoxicity assay
The cytotoxic specificity of control and CAR+ T lymphocytes was
evaluated in a standard 4–6-h chromium-51 (Cr51) release assay
using effector : target (E : T) ratios of 40 : 1, 20 : 1, 10 : 1 and 5 : 1,
as previously described.5,18 The targets tested included CAPAN-1,
CFPAC, PL45 and 293T. Target cells incubated in media alone or
in 1% Triton X-100 (Sigma-Aldrich, Inc., St Louis, MO, USA)
644 HPB
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were used to determine spontaneous and maximum Cr51 release,
respectively. The mean percentage of specific lysis of triplicate
wells was calculated as follows: ([test counts – spontaneous
counts]/[maximum counts – spontaneous counts]) ¥ 100%.
Immunohistochemistry
Pancreatic cancer cell lines and samples were resuspended in
phosphate-buffered saline (PBS), mounted onto glass slides
(Shandon Cytospin 4 Cytocentrifuge; Thermo Fisher Scientific,
Inc.,Waltham,MA, USA) and then placed in a steamer for 10 min
(high pressure) in Target Retrieval solution (Dako). Slides were
incubated in pre-block/diluent for 30 min, after which they were
incubated with rabbit anti-human PSCA antibody (AbCam, Inc.,
Cambridge, MA, USA) diluted 1 : 100 in PBS/1% bovine serum
albumin (BSA) for 1 h at room temperature. Anti-rabbit horse-
radish peroxidase (HRP) as Biotin was used to detect positive
cells, followed by enzymatic conversion using the chromogenic
substrate 3,3 diaminobenzidine (DAB).
Results
Expression of PSCA in pancreatic cancer cell lines
and tumour samples
We assessed the expression of tumour-associated antigen (TAA)
PSCA in the pancreatic cancer cell lines ASPC-1, PL45, CAPAN-1
and CFPAC by IHC, using 293T cells as a negative control cell line.
All four of the cell lines strongly overexpressed PSCA (Fig. 1) as
assessed by both IHC and quantitative real-time polymerase chain
reaction (qRT-PCR; data not shown).
To confirm that the same was true using primary tissue isolated
from pancreatic adenocarcinoma patients, we performed IHC on
paraffin-embedded tissue samples from 14 patients. We graded
the tissue samples according to the intensity of PSCA staining
(Fig. 2A). In total, eight of 14 samples (57%) were strongly PSCA-
positive, five (36%) were intermediate and one (7%) was PSCA-
negative. Figure 2B shows the staining in six individual samples
that were strongly PSCA positive. This analysis confirms that
PSCA is frequently expressed in pancreatic adenocarcinoma and
validates its usefulness as a potential target for immunotherapy.19
Generation of CAR-PSCA-modified T cells
T lymphocytes obtained from four normal donors and four
patientswith pancreatic carcinomawere activated using anti-CD3/
CD28, expanded in the presence of IL-2 (Fig. 3A) and a fraction of
the cells were transduced with a retroviral vector encoding PSCA.
Figure 3B shows the CAR-PSCA vector map. After a single trans-
duction, 53% (range: 20–92%) of healthy donor and 50% (range:
37–70%) of patient T lymphocytes expressed CAR-PSCA. Both
CD4+ and CD8+ T cells were transduced (data not shown).
Figure 3C shows a representative example of transgenic T cells and
Fig. 3D summarizes the results in all donors.
CAR-PSCA-modified T cells kill PSCA-expressing
tumour cells
To determine whether the CAR-PSCA T cells were cytolytic, we
incubated transgenic (69% transduced; data not shown) or
control (non-transduced) T cells with the PSCA-positive cell lines
PL45, CFPAC and CAPAN-1, as well as the PSCA-negative cell line
293T as a negative control. Specific Cr51 release was measured
4–6 h after co-incubation. At E : T ratios ranging from 40 : 1 to
5 : 1, CAR-PSCA T cells killed PL45, CFPAC and CAPAN-1 cell
lines (Cr51 release of 46%, 55% and 76%, respectively, at E : T
40 : 1), but achieved minimal recognition of control 293T cells
(Cr51 release: 29%). By contrast, control, non-transduced T cells
showed minimal or no specific recognition of the target PSCA-
Control - 293T ASPC-1 CAPAN-1
CFPAC-1 PL45
Figure 1 Prostate stem cell antigen (PSCA) expression in pancreatic cancer cell lines. The pancreatic cancer cell lines ASPC-1, CAPAN-1,
CFPAC and PL45 were analysed for PSCA expression by immunohistochemistry. Expression of PSCA was strong in all four lines tested,
but not in the 293T cells used as a control
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positive cell lines (Cr51 release of 22%, 17% and 42%, respectively,
at E : T 40 : 1) (Fig. 4A). These results were confirmed in four
additional T cell lines generated from healthy donors. Figure 4B
shows that CAR-PSCA T cells from four additional donors
efficiently lysed the CFPAC and CAPAN-1 cell lines (Cr51 release of
30  9% and 68  9%, respectively, at an E : T ratio of 40 : 1 
standard deviation [SD]) with no recognition of control
293T cells (16  3%).
As the clinical use of CAR-PSCA T cells for the treatment of
pancreatic cancer relies on the generation of T cell lines from
autologous PBMCs, we next determined whether our generation
protocol would be effective in material from patients who had
been heavily treated with lymphocyte-directed chemotherapy and
irradiation. Figure 4C shows that CAR-PSCA T cells from three
patients with pancreatic adenocarcinoma efficiently lysed the
CFPAC and CAPAN-1 cell lines (achieving lysis of 28 20% and
60  11%, respectively, at E : T 40 : 1  SD) with no recognition
of control 293T cells (16  15% lysis).
Discussion
Pancreatic cancer is an aggressive and lethal disease which is highly
resistant to conventional treatments. As a result of its rapid pro-
gression, absence of symptoms and lack of early screening
methods, most patients are diagnosed when the disease is already
advanced and when conventional treatments such as surgery, che-
motherapy and radiation therapy are mostly ineffective. Adoptive
transfer of T lymphocytes genetically modified to express CARs
targeting TAAs is an attractive treatment alternative and hence, to
assess the feasibility of this approach, we cloned a novel CAR
targeting the frequently expressed TAA PSCA, which is commonly
expressed in themajority of pancreatic adenocarcinomas.Wedem-
onstrated in vitro that activated T lymphocytes, derived from both
healthy donors and patients, can be readily prepared in large
numbers and canbe efficiently gene-modified to express this recep-
tor. Finally, we showed that these CAR-PSCA-expressing T cells
efficiently kill PSCA-positive pancreatic cancer cell lines in vitro.
Adoptive T cell transfer offers a real therapeutic alternative to
patients with pancreatic cancer, not only because this treatment
has the ability to target chemoresistant tumours, but also because
the infused T cells can target even disseminated disease with few
side-effects compared with conventional therapies. However, the
efficacy of any T cell-based therapy relies heavily on the nature of
the antigen(s) targeted. The ideal target antigen should be
expressed on the tumour cell surface, and uniquely or highly
expressed by tumour cells compared with normal tissues in order
NegativeIntermediateHigh
(A)
(B)
Figure 2 Prostate stem cell antigen (PSCA) expression in primary tumour samples. To assess whether PSCA was also frequently expressed
in primary tissue samples obtained from patients with pancreatic cancer, 14 samples were stained and antigen expression evaluated by
immunohistochemistry. (A) The grading strategy used to assess expression based on the intensity of PSCA staining. (B) Examples of tumour
isolates from six patients deemed to be highly PSCA-positive
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to limit collateral damage. It should also be directly involved in
maintaining the oncogenic tumour phenotype, thereby limiting
the emergence of tumour escape mutants. In the current study, we
focused on preparing T cells specific to the TAA PSCA. Cheever
et al. recently identified PSCA as a high-priority target for cancer
therapy based upon criteria including tumour specificity, oncoge-
nicity, expression level and number of identified epitopes.20 The
PSCA gene encodes a 123-amino acid glycoprotein, with 30%
homology to stem cell antigen 2 (Sca 2), and, like Sca-2, PSCA
belongs to a member of the Thy-1/Ly-6 family and is anchored by
a GPI linkage. It was originally identified as a potential target for
adoptive immunotherapy in the context of prostate cancer, in
which its overexpression was found to correlate with disease pro-
gression and prognosis. However, it has subsequently been found
to be overexpressed in a broad spectrum of tumours, including
non-small cell lung carcinoma, bladder cancer and pancreatic
cancer.11,19 The function of PSCA is unknown, but anti-PSCA
antibodies and Fab fragments have been shown to inhibit tumour
growth in pancreatic xenograft models,19,21 whereas vaccine
studies targeting PSCA induced effective antitumour immune
responses in vivo, resulting in the inhibition of tumour growth
and metastasis in a prostate cancer xenograft model and no evi-
dence of collateral autoimmune responses in normal tissues,22
thus establishing this antigen as an attractive target antigen for
immunotherapy.
Chimeric antigen receptor-modified T cells have been adop-
tively transferred to a wide spectrum of patients as tumour immu-
notherapy. The infused cells have been modified with a variety of
receptors. ‘First generation’ CARs consist of a tumour-directed
scFV linked to the transmembrane and intracellular signalling
domains of either CD3z or FcRg. ‘Second and third generation’
constructs contain additional intracellular endodomains added to
enhance in vivo T cell function by enabling cytokine production
in the absence of co-stimulation, which is often lacking on tumour
cells, and improving effector function.9 In the current study, we
developed a first-generation ‘humanized’ CAR targeting PSCA for
two main reasons.14,15 Firstly, the infusion of T cells modified with
this CAR should not be inherently immunogenic, a problem
which has been encountered in previous studies using T cells
modified with receptors derived from murine antibodies.23 For
example, Lamers and colleagues used a CAR targeting carbonic
anhydrase as treatment for renal cell carcinoma in three patients,
all of whom mounted anti-scFv antibody responses, directed
against the murine portion of the CAR.24 Secondly, there have
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Figure 4 Chimeric antigen receptor
(CAR) prostate stem cell antigen (PSCA)
T cells are cytotoxic in vitro. (A) To deter-
mine whether the CAR-PSCA T cells
could lyse tumour antigen-expressing
target cells, we tested the ability of a line
generated from a representative donor to
kill PSCA-expressing tumour cell lines
PL45, CAPAN-1 and CFPAC in a stan-
dard 6-h Cr51 release assay. The PSCA
negative cell line 293T served as a
control. Effector : target (E : T) ratios of
40 : 1, 20 : 1, 10 : 1 and 5 : 1 were
tested. (B) Summary of results using
CAR-PSCA T cells from four healthy
donors. (C) Summary of results using
CAR-PSCA T cells from four pancreatic
cancer patients. , CAR-PSCA cells; ,
non-treated T cells
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been recent reports of toxicity associated with the infusion of high
numbers of T cells modified with second- and third-generation
receptors that are easily triggered by low-avidity ‘off-target’
binding to produce a potent activation signal that leads to a lethal
cytokine storm in vivo.8,25,26 We reasoned that our CAR-PSCA
receptor would be safe for infusion because: (i) PSCA expression
is highly restricted to tumours and prostate tissue,19 and (ii) this
first-generation CAR lacks co-stimulatory domains which have
previously been associated with toxicity. Fortunately, PSCA-
directed T cells induced using DNA plasmids have revealed no
major systemic toxicities22 and T cells directed against PSCA pep-
tides have been isolated from the peripheral blood of patients.27,28
Our in vitro experiments showed that CAR-PSCA T cells gen-
erated from both healthy donors and pancreatic cancer patients
were able to specifically target and efficiently and rapidly kill
PSCA-positive tumour cells. Thus, this approach deserves further
study and may represent a promising novel treatment for patients
with pancreatic cancer. Ultimately, however, a strategy in which
T cells are combined with conventional therapies may produce
maximal benefit in vivo. Previous studies have shown that engraft-
ment of transferred T cells can be facilitated by prior immun-
odepletion with chemotherapy or total body irradiation because
this favours subsequent homeostatic T cell expansion post-
infusion.10,29–31 The combination of chemotherapy with the CAR-
PSCA T cells described here may be of considerable value in the
treatment of patients with pancreatic cancer but can be extended
essentially to any patient with a PSCA-positive tumour, including
those with prostate and bladder cancer.
Conclusions
Prostate stem cell antigen is frequently expressed on the surface of
pancreatic cancer cells and can be targeted in vitro for immune-
mediated destruction using CAR-PSCA modified, adoptively
transferred T cells. The safety and efficacy of this approach indi-
cate that it deserves further study and may represent a promising
novel treatment for patients with pancreatic cancer.
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